Fulvestrant 250mg Solution for Injection

Prescriber Criteria: Consultant Oncologist

Inpatient use:
For the treatment of HR positive, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

Duration of Approval:
1 year